DiaMedica Therapeutics (DMAC) Selling, General & Administrative (2018 - 2026)
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Selling, General & Administrative (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn | 165.53 Mn |
| 10 | DiaMedica Therapeutics | 351.39 Mn | 351.39 Mn | - | 2.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.50 Mn |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 1.89 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 1.38 Mn |
| Sep 30, 2021 | 1.08 Mn |